FILTER
FILTERED INTERVIEW RESULTS
Andrea Confetti & Roberto Fanelli
EXCLUSIVE SYNTHESIS BUSINESS UNIT LEADER (AC) & CATALOGUE APIS BU DEPUTY MANAGER (RF), DIPHARMA FRANCIS
RF: "Our experience in developing proprietary chemical processes and alternative solutions to support the generic API industry has been instrumental in rapidly expanding our CDMO activities."
Daniel Palmacci
PRESIDENT, CELL & GENE DIVISION, LONZA
"We want to give patients the best access to the amazing technology and treatments being developed by cell and gene therapy innovators. This is the modality with the greatest potential in the healthcare industry today."
John Patrick Oroho
PRESIDENT AND GENERAL MANAGER, PORZIO LIFE SCIENCES
"We are always looking at new regulations in the US and worldwide: laws very seldom change incrementally, so we adapt our systems to reflect that."
Michael Quirmbach
CEO AND PRESIDENT, CORDENPHARMA
"Our main mission is the execution of a >€200 million investment into CapEx projects that will bring additional capacity and technologies online to support pharma and biotech customers as their drug development projects progress."
Christiana Bardon
CO-MANAGING PARTNER, MPM | BIOIMPACT CAPITAL
"We see this as an exciting time to be investing in record-high levels of innovation at very attractive valuations."
Debbie Hart
PRESIDENT AND CEO, BIONJ
"To ensure that New Jersey maintains this leadership position, BioNJ will continue to work with State government to support industry and stave off onerous proposals. "
Jay Shukla
PRESIDENT AND CEO, NIVAGEN PHARMACEUTICALS, INC.
"Our partners benefit from our market intelligence and cost-splitting, and we attain the manufacturing capability and resources. We will continue to grow our partnership model now that we are expecting to double our revenue."
Robert Poe
CEO, OLON RICERCA BIOSCIENCES
"What we are doing here is beginning the build-out of a high-potency API suite, so that we can get up to a few hundred grams made for early studies and transfer those processes to our sites in Italy for the clinical trial phase."
Manni Kantipudi & Ramesh Subramanian
CHIEF EXECUTIVE OFFICER (MK) & CHIEF COMMERCIAL OFFICER (RS), ARAGEN LIFE SCIENCES
"Overall, I believe the virtual biotech model is here to stay and companies will increasingly look at CRO/CDMO companies for assistance in taking drugs from discovery to commercialization."
Chris Garabedian
CHAIRMAN AND CEO, XONTOGENY, AND PORTFOLIO MANAGER, PERCEPTIVE XONTOGENY VENTURE (PXV) FUND
"Following a long period of significant investment in early-stage firms, our industry needs to allow existing investments across the industry to mature and show signs of success before driving new investments in preclinical-stage projects."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Africa Energy 2025 - Pre-release
This pre-release, containing insights from executives across leading African upstream, downstream, financing, and service providers, spotlights developments in local capabilities, infrastructure, and new projects that are driving change in some of Africa's most interesting oil and gas producing countries.
This pre-release, containing insights from executives across leading African upstream, downstream, financing, and service providers, spotlights developments in local capabilities, infrastructure, and new projects that are driving change in some of Africa's most interesting oil and gas producing countries.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
